Otsuka, Galenea Conclude Collaborate Research and Licensing Agreement

Otsuka Pharmaceutical has announced that it has concluded a collaborative research and licensing agreement with Galenea, a Massachusetts-based bioventure company, as of Jan. 8. Under this partnership, the two companies will strive to develop innovative agents for central nervous system diseases including schizophrenia and bipolar disorder. Specifically, Otsuka will contribute funds to research and development efforts, and Galenea will identify potential drug targets and conduct further research.

Japan Corporate News (http://japancorp.net/Article.Asp?Art_ID=9422)